Skip to main content

Table 2 Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables

From: X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma

  n* XIAP-C Smac XIAP-N
   PR Pvalue PR Pvalue PR Pvalue
Age        
<50 49 42(85.7%)   20(40.8%)   21(42.9%)  
≥50 53   0.789   0.145   1.000
Size   44(83.0%)   14(26.4%)   23(43.4%)  
≤5 cm 77 67(87.0%)   26(33.8%)   33(42.9%)  
>5 cm 25 19(76.0%) 0.212 8(32.0%) 1.000 11(44.0%) 1.000
LN status        
N0 39 33(84.6%)   14(35.9%)   14(35.9%)  
N1-3 63 53(84.1%) 1.000 20(31.7%) 0.672 30(47.6%) 0.305
Grade        
I 25 22(88.0%)   10(40.0%)   13(52.0%)  
II-III 77 64(83.1%) 0.755 24(31.2%) 0.468 31(40.3%) 0.356
ER        
positive 39 31(79.5%)   14(35.9%)   20(51.3%)  
negative 63 55(87.3%) 0.401 20(31.7%) 0.672 24(38.1%) 0.221
PR        
positive 44 36(81.8%)   18(40.9%)   23(52.3%)  
negative 58 50(86.2%) 0.591 16(27.6%) 0.204 21(36.2%) 0.112
HER2        
positive 94 78(83.0%)   34(36.2%)   41(43.6%)  
negative 8 8(100.0%) 0.351 0(0.0%) 0.049 3(37.5%) 1.000
XIAP-N        
positive 44 41(93.2%)   16(36.4%)   /  
negative 58 44(75.9%) 0.030 18(31.0%) 0.672 /  
  1. n*: number of cases. PR: positive rate. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively. P-values (two sided) < 0.05 were highlighted in bold.